CRISPR Gene Therapy

Applications of Genome Editing in Targeted Therapy

Introduction

Genome Editing Technologies: Facilitate the direct targeting and modification of genomic sequences in eukaryotic cells.Impact: Significant advancements in understanding genetics in diseases, therapeutic potentials.Main Technologies: Zinc-Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), and CRISPR/Cas9.

Clinical Trials:

Overview of challenges and applications in human diseases.

Overview of Genome Editing Technologies

Zinc-Finger Nucleases (ZFNs)

  • Structure: Combination of DNA-binding domains and a non-specific cleavage domain.

  • Mechanism: Targets specific DNA sequences; effective for single-gene disruptions.

  • Applications: Used for targeted gene modifications in various organisms.

Transcription Activator-Like Effector Nucleases (TALENs)

  • Structure: Uses TALE proteins, which bind to specific DNA sequences.

  • Efficiency: Better specificity and efficiency compared to ZFNs; requires less complex design.

  • Usage: Flexible use in gene editing and transcriptional modulation.

CRISPR/Cas9

  • Origins: Derived from bacterial adaptive immune systems.

  • Components: Consists of a guide RNA and Cas9 endonuclease.

  • Advantages: Easy to program, cost-effective, capable of multiple gene edits simultaneously.

  • Current Applications: Gene correction, epigenetic modifications, use in a variety of biological and medical fields.

Mechanism of Genome Editing

  • Double-Stranded Breaks (DSBs): Created by nucleases, inserting DNA at target sites leads to gene disruption or correction.

  • Repair Mechanisms:

    • Homology-Directed Repair (HDR): Accurate but less efficient, primarily active in S/G2 phases of the cell cycle.

    • Non-Homologous End Joining (NHEJ): More prevalent, less precise, can lead to mutations.

Applications in Human Diseases

Cancer Therapy

  • Role of Oncogenes and Tumor Suppressor Genes: Opportunities for genome editing to target mutations responsible for cancer.

  • Examples: ZFN-mediated targeting of BCR-ABL in CML, TALENs disrupting CCR5 for T-cell modifications in lymphoma treatment, CRISPR applications in creating cancer models for research and therapy.

Cardiovascular Diseases (CVD)

  • Gene Editing Models: CVD models using CRISPR/Cas9 to assess gene expressions, such as MHC II gene knockouts in human endothelial cells.

  • Implications: Potential for targeting specific genetic defects underlying CVD.

Metabolic Diseases

  • Models Developed: Such as obesity and diabetes using CRISPR/Cas9 to knock out genes like LepR, affecting metabolic pathways.

  • Delivery Considerations for Type 1 Diabetes:

    • The target cell population for Type 1 diabetes treatment is primarily pancreatic beta cells, which are responsible for insulin production.

    • Delivery Methods:

      • Lentiviral Vectors: They are effective for delivering genes into cells, particularly important for beta cells that have limited regenerative capacity.

      • Nanoparticles: Lipid nanoparticles can encapsulate CRISPR components for direct injection or oral delivery, minimizing degradation and enhancing uptake by target cells. This method can provide targeted delivery to beta cells.

      • Electroporation: Utilizing an electrical field increases cell permeability, allowing CRISPR components to enter pancreatic cells to promote the regeneration of insulin-producing beta cells.

      • In Vivo Delivery: Techniques like hydrodynamic intravascular injection can facilitate the direct administration of CRISPR components into the bloodstream, improving the likelihood of targeting pancreatic tissues effectively.

Neurodegenerative Diseases

  • Research Utility: Editing in Huntington's disease and Alzheimer’s models reveals insights into gene functions affecting NDs.

Ethical Considerations and Challenges

  • Ethics: Potential for unintended genetic mutations; public acceptance varies.

  • Technical Issues: Off-target effects, delivery challenges, ensuring efficiency and specificity in editing.

Clinical Trials and Future Prospects

  • Current Status of Trials: Various trials involving ZFNs, TALENs, and CRISPR/Cas9 targeting diseases such as HIV, cancers, hemophilia, and more.

  • Future Directions: Continued improvement in specificity, delivery systems, exploring combination therapies for enhanced efficacy.

  • Innovative Applications: CRISPR for gene diagnostics and screening functional genes related to drug responses.

Conclusion

  • Therapeutic Potential: Genome editing is a promising field with diversifying applications in treating various human diseases, including Type 1 diabetes, yet the journey towards widespread clinical use remains ongoing.